Posted in Clinical Data New data build case for Roche’s oral BTK drug for MS April 22, 2026 Pharmaphorum Roche remains confident in the prospects for its soon-to-be-filed oral BTK drug fenebrutinib for multiple sclerosis, despite safety concerns. Clinical DataNeuroscienceRead full story